Executive Vice President and Chief Financial Officer · Ultragenyx Pharmaceutical Inc. (RARE)

Shalini Sharp

A named executive officer of Ultragenyx Pharmaceutical in every fiscal year CompBrief holds from FY2016 to FY2020. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2020

$793,249

Salary $499,638Stock awards $0

FY2019: $2,605,521

6th of 6 named executive officers at Ultragenyx Pharmaceutical by FY2020 total.

6 named officers on file for Ultragenyx Pharmaceutical, FY2020

Shalini Sharp’s pay file — $29

  • 5 fiscal years of pay, line by line
  • 5 equity grants, each cited to its filing
  • RARE’s disclosed peer group of 19 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Ultragenyx Pharmaceutical’s whole pay program stands against its peers

  • Ultragenyx Pharmaceutical’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on RARE→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 29, 2021 (DEF 14A).

Free

Get Shalini Sharp’s full pay file as a PDF — free

More than this page: up to 10 years of Shalini’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Shalini Sharp compensation by year

Ultragenyx Pharmaceutical Summary Compensation Table · all 5 fiscal years held
In US dollars, as Ultragenyx Pharmaceutical reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2016FY2017FY2018FY2019FY2020
Salary$441,000$455,785$491,369$484,548$499,638
Bonus$0$0$0$0$0
Stock awards$282,280$424,043$339,010$945,700$0
Option awards$1,025,693$1,541,879$1,019,820$923,758$0
Non-equity incentive$185,220$188,315$198,695$218,178$293,612
Pension and deferred compensation$0$0$0$0$0
All other$32,218$32,697$32,827$33,337$0
Total$1,966,411$2,642,719$2,081,721$2,605,521$793,249

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Ultragenyx Pharmaceutical Inc. DEF 14A filed April 29, 2021, accession 0001308179-21-000276, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Ultragenyx Pharmaceutical Inc. filed document, accession 0001308179-21-000276. Every figure is read from that document and cited to the page and table it appears in. Filed April 29, 2021.

$2.0M
$2.6M
$2.1M
$2.6M
$793K
FY16
FY17
FY18
FY19
FY20
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2020 year-end
TypeUnvested unitsValue at year-endExercise price
RSU9,775$1,353,153—
RSU3,500$484,505—
RSU1,434$198,509—
RSU1,000$138,430—
Option1,750—$88.80
Option10,937—$48.43
Option12,937—$67.55

Per the Outstanding Equity Awards at Fiscal Year-End table in Ultragenyx Pharmaceutical Inc.'s FY2020 proxy; value at the fiscal year-end close, as the company printed it.

Ultragenyx Pharmaceutical’s named executive officers, FY2020

as the company reported each
Named executive officerRoleFY2020 total
Mardi DierChief Financial Officer and Executive Vice President$6,120,642
Emil KakkisPresident and Chief Executive Officer$5,144,220
Erik HarrisChief Commercial Officer and Executive Vice President$2,224,299
Camille BedrosianExecutive Vice President and Chief Medical Officer$2,214,680
John PinionChief Quality Officer and Executive Vice President, Translational Sciences$2,177,640
Shalini Sharp · this pageExecutive Vice President and Chief Financial Officer$793,249

The full Ultragenyx Pharmaceutical compensation record

free company brief

This page is one person within Ultragenyx Pharmaceutical's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Ultragenyx Pharmaceutical proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Ultragenyx Pharmaceutical's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Shalini Sharp's compensation dossier · One-time report. No refunds.